〔Abstract〕 Objective To investigate the application value of oxaliplatin intervention in patients with early and middle stage primary hepatic carcinoma. Methods 60 patients with early and intermediate primary liver cancer admitted to Fuzhou First Hospital Affiliated to Fujian Medical University from January 2019 to December 2020 were selected. All patients received transcatheter hepatic arterial chemoembolization (TACE), and were randomly divided into control group and observation group, with 30 patients in each group. The control group was treated with pirubicin on the basis of TACE, while the observation group was treated with oxaliplatin on the basis of the control group, and the therapeutic effects of the two groups were compared. Results The total effective rate in observation group was 88.33%, which was higher than 66.67% in control group, and the difference was statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion The interventional treatment with pirubicin and oxaliplatin in combination with TACE is more ideal for patients with early and middle stage primary hepatic carcinoma, without increasing the incidence of adverse reactions.